Logo image of DBVT

DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis

NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR - Currency: USD

9.13  +0.58 (+6.78%)

After market: 9.15 +0.02 (+0.22%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DBVT. DBVT was compared to 558 industry peers in the Biotechnology industry. DBVT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DBVT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DBVT has reported negative net income.
DBVT had a negative operating cash flow in the past year.
In the past 5 years DBVT always reported negative net income.
In the past 5 years DBVT always reported negative operating cash flow.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of DBVT (-174.12%) is worse than 87.28% of its industry peers.
DBVT has a Return On Equity of -416.74%. This is in the lower half of the industry: DBVT underperforms 76.34% of its industry peers.
Industry RankSector Rank
ROA -174.12%
ROE -416.74%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

DBVT has a Gross Margin of 83.62%. This is amongst the best in the industry. DBVT outperforms 87.46% of its industry peers.
DBVT's Gross Margin has declined in the last couple of years.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DBVT has more shares outstanding
DBVT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DBVT is higher compared to a year ago.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -4.29, we must say that DBVT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.29, DBVT perfoms like the industry average, outperforming 44.09% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that DBVT is not too dependend on debt financing.
DBVT has a Debt to Equity ratio of 0.23. This is in the lower half of the industry: DBVT underperforms 70.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -4.29
ROIC/WACCN/A
WACC8.73%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

DBVT has a Current Ratio of 1.43. This is a normal value and indicates that DBVT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.43, DBVT is doing worse than 82.44% of the companies in the same industry.
DBVT has a Quick Ratio of 1.43. This is a normal value and indicates that DBVT is financially healthy and should not expect problems in meeting its short term obligations.
DBVT has a worse Quick ratio (1.43) than 81.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DBVT have decreased strongly by -53.92% in the last year.
Looking at the last year, DBVT shows a very negative growth in Revenue. The Revenue has decreased by -73.61% in the last year.
Measured over the past years, DBVT shows a very negative growth in Revenue. The Revenue has been decreasing by -22.35% on average per year.
EPS 1Y (TTM)-53.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.92%
Revenue 1Y (TTM)-73.61%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%-85.92%

3.2 Future

Based on estimates for the next years, DBVT will show a very strong growth in Earnings Per Share. The EPS will grow by 25.46% on average per year.
The Revenue is expected to grow by 152.93% on average over the next years. This is a very strong growth
EPS Next Y-5.31%
EPS Next 2Y42.2%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue Next Year2860%
Revenue Next 2Y1271.71%
Revenue Next 3Y91.26%
Revenue Next 5Y152.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DBVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DBVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

DBVT's earnings are expected to grow with 25.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.2%
EPS Next 3Y25.46%

More info and screens

0

5. Dividend

5.1 Amount

DBVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (6/6/2025, 8:00:01 PM)

After market: 9.15 +0.02 (+0.22%)

9.13

+0.58 (+6.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01
Earnings (Next)07-28 2025-07-28
Inst Owners29.72%
Inst Owner Change-9.04%
Ins Owners0.14%
Ins Owner Change-0.34%
Market Cap249.73M
Analysts88.57
Price Target13.08 (43.26%)
Short Float %0.42%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.33%
PT rev (3m)26.27%
EPS NQ rev (1m)0.06%
EPS NQ rev (3m)23.72%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-14.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.16
P/FCF N/A
P/OCF N/A
P/B 9.12
P/tB 9.13
EV/EBITDA N/A
EPS(TTM)-4.21
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)-3.86
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS0.15
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -174.12%
ROE -416.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.62%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 317.64%
Cap/Sales 56.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -4.29
F-Score1
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.92%
EPS Next Y-5.31%
EPS Next 2Y42.2%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue 1Y (TTM)-73.61%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%-85.92%
Revenue Next Year2860%
Revenue Next 2Y1271.71%
Revenue Next 3Y91.26%
Revenue Next 5Y152.93%
EBIT growth 1Y-52.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.89%
OCF growth 3YN/A
OCF growth 5YN/A